Association of markers of iron stores with outcomes in patients with nondialysis-dependent chronic kidney disease

Csaba Kovesdy, Wilber Estrada, Shahram Ahmadzadeh, Kamyar Kalantar-Zadeh

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background and objectives: Assessments of iron stores by serum iron saturation ratio (ISAT) and ferritin are used to direct anemia therapy in chronic kidney disease (CKD) and are associated with clinical outcomes in patients on dialysis. The association of ISAT and ferritin with outcomes in patients with nondialysis-dependent CKD (NDD-CKD) has not been studied. Design, setting, participants, & measurements: All-cause mortality and progression of CKD [slopes of estimated GFR (eGFR)] were examined in 453 men with NDD-CKD. Mortality and the composite of mortality and ESRD were studied in Cox models. Slopes of eGFR were examined in mixed-effects models. Results: Lower ISAT was associated with higher mortality; adjusted hazard ratio [95% confidence interval (CI)] with ISAT of <12%, 13 to 17%, and >23% versus 18 to 23%; 1.40 (0.99 to 1.98), 1.20 (0.82 to 1.76), and 0.97 (0.67 to 1.41), P = 0.025 for trend. ISAT was also associated with steeper slopes of eGFR (one log-unit higher ISAT associated with a slope of -0.89 ml/min/1.73m2 /yr (95% CI: -1.75, -0.02, P = 0.044). Serum ferritin level showed no significant association with outcomes overall, but a trend for higher mortality was observed in patients with a serum ferritin level >250 ng/ml. Conclusions: Higher ISAT is associated with lower mortality and with more progressive CKD. Clinical trials are needed to examine if correction of low iron levels can improve mortality without affecting kidney function in NDD-CKD.

Original languageEnglish (US)
Pages (from-to)435-441
Number of pages7
JournalClinical Journal of the American Society of Nephrology
Volume4
Issue number2
DOIs
StatePublished - Feb 1 2009

Fingerprint

Chronic Renal Insufficiency
Iron
Ferritins
Mortality
Serum
Confidence Intervals
Proportional Hazards Models
Chronic Kidney Failure
Anemia
Dialysis
Clinical Trials
Kidney

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation

Cite this

Association of markers of iron stores with outcomes in patients with nondialysis-dependent chronic kidney disease. / Kovesdy, Csaba; Estrada, Wilber; Ahmadzadeh, Shahram; Kalantar-Zadeh, Kamyar.

In: Clinical Journal of the American Society of Nephrology, Vol. 4, No. 2, 01.02.2009, p. 435-441.

Research output: Contribution to journalArticle

@article{8b77e05a495c4222a09e78199a23bd01,
title = "Association of markers of iron stores with outcomes in patients with nondialysis-dependent chronic kidney disease",
abstract = "Background and objectives: Assessments of iron stores by serum iron saturation ratio (ISAT) and ferritin are used to direct anemia therapy in chronic kidney disease (CKD) and are associated with clinical outcomes in patients on dialysis. The association of ISAT and ferritin with outcomes in patients with nondialysis-dependent CKD (NDD-CKD) has not been studied. Design, setting, participants, & measurements: All-cause mortality and progression of CKD [slopes of estimated GFR (eGFR)] were examined in 453 men with NDD-CKD. Mortality and the composite of mortality and ESRD were studied in Cox models. Slopes of eGFR were examined in mixed-effects models. Results: Lower ISAT was associated with higher mortality; adjusted hazard ratio [95{\%} confidence interval (CI)] with ISAT of <12{\%}, 13 to 17{\%}, and >23{\%} versus 18 to 23{\%}; 1.40 (0.99 to 1.98), 1.20 (0.82 to 1.76), and 0.97 (0.67 to 1.41), P = 0.025 for trend. ISAT was also associated with steeper slopes of eGFR (one log-unit higher ISAT associated with a slope of -0.89 ml/min/1.73m2 /yr (95{\%} CI: -1.75, -0.02, P = 0.044). Serum ferritin level showed no significant association with outcomes overall, but a trend for higher mortality was observed in patients with a serum ferritin level >250 ng/ml. Conclusions: Higher ISAT is associated with lower mortality and with more progressive CKD. Clinical trials are needed to examine if correction of low iron levels can improve mortality without affecting kidney function in NDD-CKD.",
author = "Csaba Kovesdy and Wilber Estrada and Shahram Ahmadzadeh and Kamyar Kalantar-Zadeh",
year = "2009",
month = "2",
day = "1",
doi = "10.2215/CJN.03980808",
language = "English (US)",
volume = "4",
pages = "435--441",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "2",

}

TY - JOUR

T1 - Association of markers of iron stores with outcomes in patients with nondialysis-dependent chronic kidney disease

AU - Kovesdy, Csaba

AU - Estrada, Wilber

AU - Ahmadzadeh, Shahram

AU - Kalantar-Zadeh, Kamyar

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Background and objectives: Assessments of iron stores by serum iron saturation ratio (ISAT) and ferritin are used to direct anemia therapy in chronic kidney disease (CKD) and are associated with clinical outcomes in patients on dialysis. The association of ISAT and ferritin with outcomes in patients with nondialysis-dependent CKD (NDD-CKD) has not been studied. Design, setting, participants, & measurements: All-cause mortality and progression of CKD [slopes of estimated GFR (eGFR)] were examined in 453 men with NDD-CKD. Mortality and the composite of mortality and ESRD were studied in Cox models. Slopes of eGFR were examined in mixed-effects models. Results: Lower ISAT was associated with higher mortality; adjusted hazard ratio [95% confidence interval (CI)] with ISAT of <12%, 13 to 17%, and >23% versus 18 to 23%; 1.40 (0.99 to 1.98), 1.20 (0.82 to 1.76), and 0.97 (0.67 to 1.41), P = 0.025 for trend. ISAT was also associated with steeper slopes of eGFR (one log-unit higher ISAT associated with a slope of -0.89 ml/min/1.73m2 /yr (95% CI: -1.75, -0.02, P = 0.044). Serum ferritin level showed no significant association with outcomes overall, but a trend for higher mortality was observed in patients with a serum ferritin level >250 ng/ml. Conclusions: Higher ISAT is associated with lower mortality and with more progressive CKD. Clinical trials are needed to examine if correction of low iron levels can improve mortality without affecting kidney function in NDD-CKD.

AB - Background and objectives: Assessments of iron stores by serum iron saturation ratio (ISAT) and ferritin are used to direct anemia therapy in chronic kidney disease (CKD) and are associated with clinical outcomes in patients on dialysis. The association of ISAT and ferritin with outcomes in patients with nondialysis-dependent CKD (NDD-CKD) has not been studied. Design, setting, participants, & measurements: All-cause mortality and progression of CKD [slopes of estimated GFR (eGFR)] were examined in 453 men with NDD-CKD. Mortality and the composite of mortality and ESRD were studied in Cox models. Slopes of eGFR were examined in mixed-effects models. Results: Lower ISAT was associated with higher mortality; adjusted hazard ratio [95% confidence interval (CI)] with ISAT of <12%, 13 to 17%, and >23% versus 18 to 23%; 1.40 (0.99 to 1.98), 1.20 (0.82 to 1.76), and 0.97 (0.67 to 1.41), P = 0.025 for trend. ISAT was also associated with steeper slopes of eGFR (one log-unit higher ISAT associated with a slope of -0.89 ml/min/1.73m2 /yr (95% CI: -1.75, -0.02, P = 0.044). Serum ferritin level showed no significant association with outcomes overall, but a trend for higher mortality was observed in patients with a serum ferritin level >250 ng/ml. Conclusions: Higher ISAT is associated with lower mortality and with more progressive CKD. Clinical trials are needed to examine if correction of low iron levels can improve mortality without affecting kidney function in NDD-CKD.

UR - http://www.scopus.com/inward/record.url?scp=66849126016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66849126016&partnerID=8YFLogxK

U2 - 10.2215/CJN.03980808

DO - 10.2215/CJN.03980808

M3 - Article

VL - 4

SP - 435

EP - 441

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 2

ER -